NCT06661161

Brief Summary

The goal of the study is to calibrate the algorithmic model of the TakeCoeur AI device to detect early heart failure decompensation in patients with heart failure, using physiological data (clinical) actively and passively collected through connected medical devices (watch, blood pressure monitor, and scale).

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
640

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Nov 2024

Geographic Reach
1 country

3 active sites

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 30, 2024

Completed
28 days until next milestone

First Posted

Study publicly available on registry

October 28, 2024

Completed
4 days until next milestone

Study Start

First participant enrolled

November 1, 2024

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2025

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2026

Completed
Last Updated

October 28, 2024

Status Verified

October 1, 2024

Enrollment Period

1 year

First QC Date

September 30, 2024

Last Update Submit

October 24, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Concordance between the detection of heart failure decompensation by the TakeCoeur AI device and the occurrence of heart failure decompensation

    calibrate the algorithmic model of the TakeCoeur IA device for early detection of cardiac decompensation in patients suffering from heart failure.

    From enrollment to the end of the 6-month follow-up period.

Secondary Outcomes (2)

  • Evaluate the time (in days) to anticipate cardiac decompensation

    From enrollment to the end of the 6-month follow-up period.

  • Evaluate the compliance of patients with heart failure to the Takecoeur IA device and its connected collection accessories

    From enrollment to the end of the 6-month follow-up period.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Participation in the study will be offered to any patient consulting a cardiologist/cardio-geriatrician at one of the participating centers who meets the inclusion criteria and non inclusion criteria.

You may qualify if:

  • Age ≥ 18 years
  • Patient diagnosed with chronic heart failure, confirmed by a cardiologist/cardio-geriatrician (regardless of the type and etiology of the disease), meeting at least one of the following two conditions:
  • Hospitalization in the past 12 months for a heart failure exacerbation.
  • French speaking patient
  • Patient equipped with a smartphone, computer, or tablet with internet/cellular access (of with the help of a caregiver)
  • Patient affiliated with a social security scheme

You may not qualify if:

  • Patient undergoing dialysis for renal failure
  • Patient who has received or is scheduled to receive a heart transplant or circulatory assistance within the next 12 months
  • Patient with a left ventricular ejection fraction ≥ 50% (for non-diastolic heart failure)
  • Obese patient with a body mass index ≥ 40 kg/m²
  • Patient with severe aortic stenosis who is contraindicated for surgery or TAVI
  • Patient with a life expectancy of \< 1 year due to a condition other than heart failure (cancer, cirrhosis, respiratory failure, etc.)
  • Patient already benefiting from a telemonitoring device
  • Physical or psychological inability (dementia, schizophrenia, substance-related disorder) of the patient or caregiver to use the digital data collection device, as judged by the physician
  • Patient refusal to allow the transmission of the data necessary for monitoring the effective use of the device and obtaining individualized or national real-world usage results
  • Patient under guardianship, curatorship, or any other administrative or judicial measure restricting rights and freedoms
  • Patient unable to wear the watch for the duration of the study due to skin conditions

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Chu Brest

Brest, 29609, France

Location

CH Morlaix

Morlaix, 29600, France

Location

CH Vannes

Vannes, 56000, France

Location

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 30, 2024

First Posted

October 28, 2024

Study Start

November 1, 2024

Primary Completion

November 1, 2025

Study Completion

May 1, 2026

Last Updated

October 28, 2024

Record last verified: 2024-10

Data Sharing

IPD Sharing
Will share

All collected data that underlie results in a publication

Shared Documents
STUDY PROTOCOL
Time Frame
Data will be available beginning three years and ending fifteen years following the final study report completion
Access Criteria
Data access requests will be reviewed by the internal committee of Brest UH. Requestors will be required to sign and complete a data access agreement

Locations